Is DuPont de Nemours, Inc. (DD) undervalued or overvalued?

Our model estimates a fair value of about $8 against a price of $130.45 (Data under review, +0% to fair value). It blends a 10-year DCF, sector multiples and earnings-power value and is a model estimate, not advice.

What is the X-Ray Score for DD?

DuPont de Nemours, Inc. has an X-Ray Score of 18 out of 100, built from valuation, growth, profitability, financial health and dividend lenses ranked against Industrials peers.

Where does the data for DD come from?

Financial statements come from SEC EDGAR filings, prices from exchange price feeds, and industry betas and equity risk premium from Damodaran Online (NYU Stern).

DuPont de Nemours, Inc. (DD)

Industrials · Industrial Conglomerates · US stock · S&P 500 component

$130.45 ▼ -1.15 (0.87%)

At close 16 Oct 2026 · USD · Volume 873,400

Compare with HON Historical data Research report SEC filings

Fair valueData under review

$4fair band $5–$12$13

Day's range

$130.04 – $133.17

52-week range

$95.66 – $156.04

About DuPont de Nemours, Inc.

DuPont is a materials science and technology company that supplies specialty products to industrial and healthcare markets. Its offerings include water filtration and purification technology, construction and building materials such as Tyvek, and materials used in medical devices and healthcare packaging. Customers include building product makers, water treatment operators, device makers and industrial manufacturers. The company is organised around a small number of specialty businesses.

Supplying engineered materials and technologies to manufacturers generated revenue of $7.0 billion over the last twelve months. Revenue has changed at -19.3% a year across the last three years, a steep decline. The operating margin is 6.8%, the business earns 3% on the capital invested in it, and net debt is 1.5 times EBITDA. The dividend yield is 0.9%. On the site's X-Ray Score it receives 18 out of 100.

Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.

Price chart

Historical data & CSV

52-wk range $95.66 – $156.04Volume 873,400Daily, split-adjusted

Vitals

Market cap$17.8B

52-week range$95.66 – $156.04

Volume (last day)873,400

P/E (TTM)823.6

EBIT / EV yield2.4%

Free-cash-flow yield–

Dividend yield0.9%

Revenue (TTM)$7.0B

Net income (TTM)$55M

Operating margin6.8%

Return on capital2.8%

Debt incl. leases$3.1B

Cash & securities$1.7B

Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.

Fair value estimate

$8model spread $7 – $10

Data under review +0.0% to fair value

Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is High, so the safety margin is 40%.

Multiples use through-the-cycle earnings (0.30x of the last twelve months)

Peak-cycle earnings: the current operating margin is more than 1.5x its 7-year average, so the fair value range is widened

Earnings are far above the company's own 3-year history, so models would extrapolate a possible peak

Price $130

Undervalued < $5Fair $5 – $12Overvalued > $12

10-year DCF (market-scaled)

$11

Peer multiples

$7

Earnings power floor (not blended)

$13

Fundamentals-adjusted multiple

$7

Growth the price implies

30.3%/yr

A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.

What this means

Read the lenses below

The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.

Before you invest · decision checklist

I understand how this company makes money Business quality is average or better 28 The price is not above fair value $8 fair value Debt looks manageable 1.5× EBITDA Revenue has been growing -19.3% a year Profits are backed by cash There are no red flags none raised I know what share of my savings this would be

Ticked boxes are filled in from our data; the rest are yours to answer.

The five-lens scan

Every score explained in one sentence, ranked against Industrials peers. Open a lens to see the numbers behind it.

Valuation Weak

4/100

Expensive against its sector on earnings and cash flow.

See the numbers →

EBIT / EV yield2.4%

Fair value vs price0.1×

Growth Weak

22/100

Growing slower than most of its sector.

See the numbers →

Revenue growth (3y)-19.3%

Growth consistency70%

Profitability Weak

7/100

Earns lower returns on its capital than most peers.

See the numbers →

Return on invested capital2.8%

Operating margin6.8%

Gross profitability11.7%

Financial health Weak

48/100

Balance sheet is more stretched than most peers.

See the numbers →

Piotroski F-Score6 / 9

Net debt / EBITDA1.5×

Interest coverNo interest cost

Dividends Weak

14/100

Dividend is modest or less certain than peers.

See the numbers →

Dividend yield0.9%

Dividend growth-2.9%

Quarterly results: last 6 quarters

+0.8%

Mar '25

+1.9%

Jun '25

+4.7%

Sep '25

+0.2%

Dec '25

+4.3%

Mar '26

+4.0%

Jun '26

Revenue against the same quarter a year earlier. Latest quarter revenue $1.8B, diluted EPS $1.05.

Compare with peers

HON Honeywell Internationa...55 MMM 3m Co40

Other Industrial Conglomerates companies by X-Ray Score.

Fundamentals checklist

● 2 Good · ● 3 Average · ● 7 Bad

Cash quality

Risk models

Altman Z''Bad

Piotroski F-ScoreAverage

Growth

Revenue growth (3y)Bad

Growth consistencyAverage

Balance sheet

Current ratioGood

Net debt / EBITDAAverage

Interest coverGood

Valuation

Fair value vs priceBad

EBIT / EV yieldBad

Profitability

Return on invested capitalBad

Operating marginBad

Gross profitabilityBad

Each check is graded against the company's sector, not a fixed number. Checklist score 24/100.

Financials

	FY21	FY22	FY23	FY24	FY25
Revenue	$12.6B	$13.0B	$6.6B	$6.7B	$6.8B
Operating income	$1.4B	$1.4B	−$279M	$117M	$200M
Net income	$6.5B	$5.9B	$423M	$703M	$88M
Operating cash flow	$2.3B	$588M	–	–	–
Operating margin	11.5%	11.1%	-4.2%	1.7%	2.9%
Free cash flow	$1.5B	−$74M	–	–	–
Diluted EPS	$11.89	$11.75	$0.94	$1.68	$-1.86

Fiscal years, from SEC filings.

Technical summary

Daily

Bearish

2 bullish · 4 neutral · 10 bearish

Weekly

Bearish

4 bullish · 1 neutral · 7 bearish

Monthly

Strongly bullish

6 bullish · 1 neutral · 1 bearish

Moving averages (daily)

SMA 10	130.7	Bearish
EMA 10	130.4	Bullish
SMA 20	130.6	Bearish
EMA 20	130.6	Bearish
SMA 50	133.3	Bearish
EMA 50	132.5	Bearish
SMA 100	136.2	Bearish
EMA 100	134.2	Bearish
SMA 200	137.2	Bearish
EMA 200	131.4	Bearish

Oscillators (daily)

RSI (14)	48.53	Neutral
MACD (12, 26)	-0.52	Bearish
Momentum (12)	0.43	Bullish
Stochastic %K (14)	44.96	Neutral
Williams %R (14)	-55.04	Neutral
CCI (20)	65.68	Neutral

Pivot points (classic, last session)

126.1

128.1

129.3

Pivot

131.2

132.4

134.4

135.5

Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.

Dividends

Paid, last 12 months

1.20 USD

Yield on today's price

0.92%

Frequency

Quarterly

Next ex-dividend date

30 Nov 2026

Ex-dividend date	Amount per share
30 Nov 2026 (upcoming)	0.6000
31 Aug 2026	0.6000
15 May 2026	0.2000
2 Mar 2026	0.2000
28 Nov 2025	0.2000
29 Aug 2025	0.4100
30 May 2025	0.4100
3 Mar 2025	0.4100
29 Nov 2024	0.3800
30 Aug 2024	0.3800
31 May 2024	0.3800
28 Feb 2024	0.3800